Aquila BioMedical is an innovative preclinical contract research organization that offers clients world leading research expertise in Immuno- Oncology, Immunology and Histology.
Bespoke services combine advanced models with protocolled techniques, to provide high-value data, defining both efficacy and the mechanism of action of drug candidate compounds. A key feature of the Aquila offering is the partnering of services with world-leading academics to provide expert advice and interpretation of the data.
Aquila has developed novel technologies to help you better understand the cellular and molecular events that occur with compound administration. Our assays allow both Phenotypic Screening and target based research methods. This enables hit identification and optimisation of compound and target selection, directly increasing the compound success rate and reducing the overall cost associated with drug development.